Vanguard Group Inc Janux Therapeutics, Inc. Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 1,357,960 shares of JANX stock, worth $56.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,357,960

Previous 979,483 38.64%

Holding current value

$56.3 Million

Previous $10.5 Million 386.51%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	BUY	$7.93 - $49.75 $3 Million - $18.8 Million	378,477 Added 38.64%	1,357,960 $51.1 Million
Q4 2023 Feb 14, 2024	BUY	$5.85 - $11.7 $217,631 - $435,263	37,202 Added 3.95%	979,483 $10.5 Million
Q3 2023 Nov 14, 2023	BUY	$9.56 - $14.0 $1.72 Million - $2.52 Million	180,291 Added 23.66%	942,281 $9.5 Million
Q2 2023 Aug 14, 2023	SELL	$11.08 - $15.92 $118,168 - $169,786	-10,665 Reduced 1.38%	761,990 $9.04 Million
Q1 2023 May 15, 2023	BUY	$11.25 - $22.21 $202,893 - $400,557	18,035 Added 2.39%	772,655 $9.35 Million

Q4 2022 Feb 10, 2023	SELL	$11.1 - $18.26 $64,979 - $106,894	-5,854 Reduced 0.77%	754,620 $9.94 Million
Q3 2022 Nov 14, 2022	BUY	$10.82 - $16.84 $1.2 Million - $1.87 Million	110,834 Added 17.06%	760,474 $10.3 Million
Q2 2022 Aug 12, 2022	BUY	$9.52 - $15.65 $796,452 - $1.31 Million	83,661 Added 14.78%	649,640 $7.93 Million
Q1 2022 May 13, 2022	BUY	$13.24 - $20.24 $435,701 - $666,057	32,908 Added 6.17%	565,979 $8.12 Million
Q4 2021 Feb 14, 2022	BUY	$15.44 - $27.32 $43,679 - $77,288	2,829 Added 0.53%	533,071 $10.5 Million
Q3 2021 Nov 12, 2021	BUY	$20.7 - $34.69 $10.4 Million - $17.4 Million	501,266 Added 1729.94%	530,242 $11.5 Million
Q2 2021 Aug 13, 2021	BUY	$18.58 - $25.37 $538,374 - $735,121	28,976 New	28,976 $723,000

Others Institutions Holding JANX

# of Institutions

123

Shares Held

25.3M

Call Options Held

92K

Put Options Held

161K

View Full List

About Janux Therapeutics, Inc.

Ticker JANX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 41,663,000
Market Cap $1.73B
Description
Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...

More about JANX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Janux Therapeutics, Inc. Transaction History